Arcutis Biotherapeutics (ARQT) Q2 2024: Zareve Scripts Jump 42% as Indications Expand, Primary Care Push Builds for 2025
Arcutis Biotherapeutics delivered another quarter of sharply accelerating prescription growth, with Zareve’s portfolio volume up 42% QoQ as the atopic dermatitis launch begins to contribute and gross-to-net improvements persist. The company’s strategic expansion into primary care and pediatric channels, enabled by the COA partnership, sets the stage for a broader prescriber base in 2025. Investor focus now shifts to execution in new indications and the operational leverage from expanding covered scripts and payer access.
Summary
- Prescription Growth Outpaces Expectations: Zareve portfolio scripts surged on new launches and access wins.
- Primary Care Channel Expansion: COA partnership unlocks new prescriber segments for 2025 growth.
- Operational Leverage in Focus: Gross-to-net and access gains position ARQT for margin improvement ahead.
Business Overview
Arcutis Biotherapeutics develops and commercializes topical therapies for chronic dermatologic diseases, primarily through its Zareve product line. The company generates revenue from prescription sales of Zareve cream and foam, which target psoriasis, seborrheic dermatitis (seb derm), and, most recently, atopic dermatitis (AD). Its business is anchored in dermatology, but is now expanding into primary care and pediatric segments via a co-promotion partnership with COA Pharmaceuticals.
Performance Analysis
Net product revenues reached $30.9 million for the quarter, with Zareve cream and foam contributing 56% and 44% respectively, reflecting a 43% sequential increase. The Zareve portfolio achieved nearly 10,000 weekly scripts at peak, with total prescriptions surpassing 351,000 from over 14,000 prescribers to date. The launch of the atopic dermatitis indication in late July is expected to further accelerate prescription growth in the second half of 2024.
Gross-to-net (GTN) improvements remain a key driver, as blended GTN fell into the high 50s, down from the low 60s in the prior quarter, driven by expanded payer coverage and improved prescription pull-through. The cream’s GTN has stabilized at its expected steady state, with future improvements expected mainly from the foam. On the expense side, R&D declined YoY due to lower development costs, while SG&A rose on field force expansion and stock comp, but management signaled ongoing cost discipline and operational leverage as revenue scales.
- Script Mix Shift: Foam prescriptions are growing faster than cream, reflecting larger addressable markets and less competition in seb derm.
- Refill Rate Signal: Psoriasis refill rates at 38% signal durable patient engagement, with seb derm expected to trend even higher.
- Access Expansion: Four out of five cream scripts and three out of four foam scripts are now covered, a high benchmark in branded topicals.
Cash burn was $45 million for the quarter, with $363 million in cash and marketable securities providing ample runway for commercial execution and pipeline development. Leadership reiterated no need for further equity raises to support existing business lines.
Executive Commentary
"We saw strong growth during the quarter in our expanding Zareve portfolio as healthcare providers and their patients see how Zareve cream and Zareve foam address real needs in the treatment of psoriasis and seborrheic dermatitis, respectively."
Frank Watanabe, President and CEO
"Our current capital together with our product revenues enable us to continue operating the business for the foreseeable future, including our continued investment in commercial launches. As we've said repeatedly, we do not envision a need to come back to the equity market to support our existing businesses."
David Topper, Chief Financial Officer
Strategic Positioning
1. Portfolio Expansion and Indication Sequencing
Arcutis is executing a multi-indication strategy with Zareve, now covering psoriasis, seb derm, and atopic dermatitis, with a fourth indication (scalp and body psoriasis for foam) filed and pending FDA approval. This approach maximizes brand leverage and simplifies prescribing for dermatologists, creating a “one-stop” topical solution for chronic skin conditions.
2. Payer Access and Gross-to-Net Optimization
Securing broad coverage from all three major pharmacy benefit managers (PBMs) has driven higher covered script rates and gross-to-net improvements. Medicaid and Medicare access is expanding, and management expects gross-to-net ratios for these channels to remain comparable to commercial, reflecting strategic WAC pricing below specialty thresholds.
3. Primary Care and Pediatric Channel Expansion
The COA Pharmaceuticals co-promotion deal opens up the much larger primary care and pediatric prescriber base, which is critical for atopic dermatitis and seb derm market penetration. COA’s dedicated sales force will begin field promotion by year-end, with revenue impact expected from 2025 onward as education and awareness build in these channels.
4. Pipeline and Business Development Discipline
Pipeline progress continues with ARQ234 (CD200 receptor agonist) IND filing targeted for 2025, and a pediatric atopic dermatitis SNDA planned for Q1 2025. Management emphasized a high bar for business development, focusing on strategic fit and value creation rather than revenue roll-ups, enabled by improved debt flexibility following the SLR amendment.
5. Operational Leverage and Cost Management
SG&A growth is tied to launch investments and field force expansion, but management expects increasing economies of scale, especially as the COA partnership drives incremental revenue without proportional expense growth. G&A discipline and one-time launch costs are expected to moderate, supporting progress toward profitability as revenue accelerates.
Key Considerations
This quarter marks a pivotal inflection as Zareve’s multi-indication momentum, payer access, and channel expansion converge, but execution in new segments and continued gross-to-net management will determine the durability of growth and margin expansion.
Key Considerations:
- Primary Care Ramp Timing: COA’s impact will be back-end loaded, with meaningful revenue contribution expected in 2025, not 2024.
- Coverage and Access Wins: Further Medicaid and Medicare access could accelerate script growth and stabilize gross-to-net ratios.
- Refill and Adherence Trends: Durable refill rates, especially in seb derm and AD, are critical for maximizing lifetime value per patient.
- Pipeline Milestones: Progress on ARQ234 and pediatric AD filings will shape medium-term growth optionality and investor sentiment.
Risks
Execution risk remains in scaling primary care and pediatric channels, where prescriber education and awareness lag dermatology. Payer dynamics, especially in Medicaid and Medicare, could shift gross-to-net assumptions. Competitive pressure from new entrants or alternative therapies in atopic dermatitis and psoriasis may challenge share gains, while any delays in pipeline approvals or access expansion could slow the growth trajectory.
Forward Outlook
For Q3 2024, Arcutis expects:
- Continued prescription and revenue growth from Zareve, driven by atopic dermatitis launch and seasonal demand.
- Steady-state gross-to-net ratios in the high 50s, with further improvement possible for foam.
For full-year 2024, management maintained guidance for:
- Sustained revenue momentum and operational runway without additional equity financing.
Management emphasized several drivers:
- Primary care and pediatric channel contributions will be modest in 2024, but foundational for 2025.
- Medicaid and Medicare access expansion and payer negotiations are ongoing, with potential for incremental upside.
Takeaways
Arcutis is demonstrating that multi-indication portfolio leverage, payer access, and channel expansion can drive robust top-line growth and set the stage for future margin improvement.
- Script Growth Outpaces Market: Zareve’s portfolio volume and refill rates highlight strong clinical adoption and patient retention.
- Channel Diversification Underway: The COA partnership broadens Arcutis’ addressable market, with primary care and pediatric impact expected to build in 2025.
- Margin Expansion Watchpoint: Gross-to-net improvements and SG&A leverage are key to future profitability as revenue scales and launch costs moderate.
Conclusion
Arcutis Biotherapeutics is executing on a multi-pronged growth strategy, with Zareve’s expanding indications, payer access, and new channel partnerships supporting sustained revenue acceleration. The next phase will test the company’s ability to convert expanded access and prescriber reach into durable, profitable growth.
Industry Read-Through
Arcutis’ experience underscores the importance of payer access, indication expansion, and channel diversification for specialty pharma in dermatology and beyond. The COA partnership model may become a template for other biotechs seeking to penetrate primary care and pediatric segments without incurring full SG&A burden. Gross-to-net optimization and strategic pricing below specialty thresholds are critical levers for margin preservation as public payer mix rises. Competitors in chronic dermatology and adjacent therapeutic areas should watch for increased formulary competition and shifting prescriber dynamics as multi-indication brands consolidate share.